BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 30922328)

  • 21. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
    Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
    Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive DNA repair gene expression analysis and its prognostic significance in acute myeloid leukemia.
    Park S; Kim YJ; Huh HJ; Chung HS; Lee M; Park YM; Mun YC; Seong CM; Huh J
    Hematology; 2021 Dec; 26(1):904-913. PubMed ID: 34789078
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Zhang TJ; Zhou JD; Zhang W; Lin J; Ma JC; Wen XM; Yuan Q; Li XX; Xu ZJ; Qian J
    Clin Epigenetics; 2018; 10():47. PubMed ID: 29643943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia.
    Lian XY; Ma JC; Zhou JD; Zhang TJ; Wu DH; Deng ZQ; Zhang ZH; Li XX; He PF; Yan Y; Lin J; Qian J
    J Cell Physiol; 2019 Jun; 234(6):9438-9446. PubMed ID: 30317626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia.
    Laverdière I; Boileau M; Neumann AL; Frison H; Mitchell A; Ng SWK; Wang JCY; Minden MD; Eppert K
    Blood Cancer J; 2018 Jun; 8(6):52. PubMed ID: 29921955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations.
    Ryotokuji T; Yamaguchi H; Ueki T; Usuki K; Kurosawa S; Kobayashi Y; Kawata E; Tajika K; Gomi S; Kanda J; Kobayashi A; Omori I; Marumo A; Fujiwara Y; Yui S; Terada K; Fukunaga K; Hirakawa T; Arai K; Kitano T; Kosaka F; Tamai H; Nakayama K; Wakita S; Fukuda T; Inokuchi K
    Haematologica; 2016 Sep; 101(9):1074-81. PubMed ID: 27247325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
    Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
    Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.
    Duployez N; Marceau-Renaut A; Villenet C; Petit A; Rousseau A; Ng SWK; Paquet A; Gonzales F; Barthélémy A; Leprêtre F; Pottier N; Nelken B; Michel G; Baruchel A; Bertrand Y; Leverger G; Lapillonne H; Figeac M; Dick JE; Wang JCY; Preudhomme C; Cheok M
    Leukemia; 2019 Feb; 33(2):348-357. PubMed ID: 30089916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
    Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
    J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
    Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
    BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia.
    Tao YF; Fang F; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Li ZH; Wang NN; Xu LX; Du XJ; Sun LC; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
    BMC Cancer; 2015 Oct; 15():756. PubMed ID: 26490736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia.
    Sun GK; Tang LJ; Zhou JD; Xu ZJ; Yang L; Yuan Q; Ma JC; Liu XH; Lin J; Qian J; Yao DM
    Cancer Med; 2019 Oct; 8(14):6393-6402. PubMed ID: 31486300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks.
    Deneberg S; Guardiola P; Lennartsson A; Qu Y; Gaidzik V; Blanchet O; Karimi M; Bengtzén S; Nahi H; Uggla B; Tidefelt U; Höglund M; Paul C; Ekwall K; Döhner K; Lehmann S
    Blood; 2011 Nov; 118(20):5573-82. PubMed ID: 21960591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Wang WD
    Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia.
    Zhang H; Zhang N; Wang R; Shao T; Feng Y; Yao Y; Wu Q; Zhu S; Cao J; Zhang H; Li Z; Liu X; Niu M; Xu K
    J Transl Med; 2019 Apr; 17(1):106. PubMed ID: 30935386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
    Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
    J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct confirmation of quiescence of CD34+CD38- leukemia stem cell populations using single cell culture, their molecular signature and clinicopathological implications.
    Won EJ; Kim HR; Park RY; Choi SY; Shin JH; Suh SP; Ryang DW; Szardenings M; Shin MG
    BMC Cancer; 2015 Apr; 15():217. PubMed ID: 25881148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.
    Shi J; Fu H; Jia Z; He K; Fu L; Wang W
    EBioMedicine; 2016 Dec; 14():55-64. PubMed ID: 27916548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.